High density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Whether HDL is associated with dementia risk is unclear. In addition to apoA1, other apolipoproteins are found in HDL, creating subspecies of HDL that may have distinct metabolic properties. We measured apoA1, apoC3, and apoJ levels in plasma and apoA1 levels in HDL that contains or lacks apoE, apoJ, or apoC3 using a modified sandwich ELISA in a case-cohort study nested within the Ginkgo Evaluation of Memory Study. We included 995 randomly selected participants and 521 participants who developed dementia during a mean of 5.1 years of follow-up. The level of total apoA1 was not significantly related to dementia risk, regardless of the coexistence of apoC3, apoJ, or apoE. Higher levels of total plasma apoC3 were associated with better cognitive function at baseline (difference in Modified Mini-Mental State Examination scores tertile 3 vs. tertile 1: 0.60; 95% CI: 0.23, 0.98) and a lower dementia risk (adjusted hazard ratio tertile 3 vs. tertile 1: 0.73; 95% CI: 0.55, 0.96). Plasma concentrations of apoA1 in HDL and its apolipoprotein-defined subspecies were not associated with cognitive function at baseline or with the risk of dementia during follow-up. Similar studies in other populations are required to better understand the association between apoC3 and Alzheimer's disease pathology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Chui, H. C., Victoroff, J. I., Margolin, D., Jagust, W., Shankle, R., & Katzman, R. (1992) · Neurology · doi:10.1212/wnl.42.3.473 · Cited by 1,201
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Incidence of dementia over three decades in the Framingham heart study
Satizabal, C. L., Beiser, A. S., Chouraki, V., Chêne, G., Dufouil, C., & Seshadri, S. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1504327 · Cited by 1,051 · cited 1×
“factors over the last decades, the prevalence of dementia is increasing dramatically in aging societies (2).”
BackgroundVaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942 · cited 2×
“Males 534 (54) 265 (51) Age (years) 78 (75, 85) 79 (75, 87) APOE Ɛ4 allele carrier 180 (18) 144 (28) Whites 951 (96) 489 (94) Education (years) 14 (10, 20) 14 (8, 20) Current alcohol drinker 257 (50) 528 (54) Current smoking 40 (4) 20 (4) BMI, kg/m(2) 27 (21, 35) 26 (21, 34) Lipid-lowering medication use 267 (27) 160…”
BackgroundChatterjee, S., Peters, S. A. E., Woodward, M., Mejia Arango, S., Batty, G. D., Beckett, N., Beiser, A., Borenstein, A. R., Crane, P. K., Haan, M., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1588 · Cited by 711 · cited 2×
“risk factors for dementia (20, 21), we examined the associa-”
BackgroundObesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II study
Singh‐Manoux, A., Dugravot, A., Shipley, M., Brunner, E. J., Elbaz, A., Sabia, S., & Kivimaki, M. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2637 · Cited by 401 · cited 1×
“First, weight loss has been shown to lower plasma apoC3 level (54), and unintended weight loss has been described as a common finding in the preclinical stage of dementia (55),”
BackgroundAnstey, K. J., Ashby-Mitchell, K., & Peters, R. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160826 · Cited by 360
Wolters, F. J., Segufa, R. A., Darweesh, S. K. L., Bos, D., Ikram, M. A., Sabayan, B., Hofman, A., & Sedaghat, S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.007 · Cited by 293 · cited 2×
“risk factors for dementia (20, 21), we examined the associa-”
BackgroundPlasma clusterin and the risk of Alzheimer disease
Schrijvers, E. M. C. (2011) · JAMA · doi:10.1001/jama.2011.381 · Cited by 220 · cited 2×
“7-year follow-up period in the Rotterdam study (55).”
BackgroundCirculating metabolites and general cognitive ability and dementia: evidence from 11 cohort studies
van der Lee, S. J., Teunissen, C. E., Pool, R., Shipley, M. J., Teumer, A., Chouraki, V., Melo van Lent, D., Tynkkynen, J., Fischer, K., Hernesniemi, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.012 · Cited by 197 · cited 3×
“dementia risk in some studies (10, 11), the overall evi-”
BackgroundDeKosky, S. T., Fitzpatrick, A., Ives, D. G., Saxton, J., Williamson, J., Lopez, O. L., Burke, G., Fried, L., Kuller, L. H., Robbins, J., et al. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2006.02.007 · Cited by 176 · cited 1×
“If scores on the 3MSE, Clinical Dementia Rating, or ADAS-cog declined by a predefined threshold, the neuropsychological battery was readministered (22).”
MethodSelf-citationPlasma levels of apolipoprotein Eand risk of dementia in the general population
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2015) · Annals of Neurology · doi:10.1002/ana.24326 · Cited by 156 · cited 4×
“dementia risk in some studies (10, 11), the overall evi-”
BackgroundInfluentialWyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134
Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
Koch, M., Furtado, J. D., Falk, K., Leypoldt, F., Mukamal, K. J., & Jensen, M. K. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.007 · Cited by 31
Self-citation
Cited by
Wolters, F. J., Segufa, R. A., Darweesh, S. K. L., Bos, D., Ikram, M. A., Sabayan, B., Hofman, A., & Sedaghat, S. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.007 · Cited by 293
Association between lipid metabolism and cognitive function in patients with schizophrenia
Liu, H., Huang, Z., Zhang, X., He, Y., Gu, S., Mo, D., Wang, S., Yuan, Z., Huang, Y., Zhong, Q., et al. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1013698 · Cited by 40
Urinary Apolipoprotein C3 Is a Potential Biomarker for Alzheimer’s Disease
Watanabe, Y., Hirao, Y., Kasuga, K., Tokutake, T., Kitamura, K., Niida, S., Ikeuchi, T., Nakamura, K., & Yamamoto, T. (2020) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000509561 · Cited by 38
Association of Apolipoprotein E in Lipoprotein Subspecies With Risk of Dementia
Koch, M., DeKosky, S. T., Goodman, M., Sun, J., Furtado, J. D., Fitzpatrick, A. L., Mackey, R. H., Cai, T., Lopez, O. L., Kuller, L. H., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.9250 · Cited by 34
Self-citation
Metadata
- Authors
- Koch, M., DeKosky, S. T., Goodman, M., Sun, J., Furtado, J. D., Fitzpatrick, A. L., Mackey, R. H., Cai, T., Lopez, O. L., Kuller, L. H., Mukamal, K. J., & Jensen, M. K.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2020-03
- Volume
- 61
- Issue
- 3
- Pages
- 445-454
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2997147481
- Cited by
- 29
- References
- 17
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.